Third Circuit Nixes Antitrust Action Against Merck Alleging Mumps Vaccine Labeling Thwarted Competition
- October 11, 2024
Merck & Co, Inc.does not have to face a class action alleging it violated the antitrust laws by misrepresenting the end-of-shelf-life potency of its mumps vaccine to prevent a competitor from entering the market, the Third Circuit held October 7 in an unpublished opinion.
ARTICLE TAGS
You must be logged in to access this content.